The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease.

"Declaration of Competing Interest: D.J.S. has consulted for Cadent Therapeutics, Neurodon and Lundbeck in the last two years; he is a co-founder of Cavalon Therapeutics. P. B. has consulted for Axial Therapeutics, Calico, CuraSen, Enterin Inc., Fujifilm-Cellular Dynamics Inc., Idorsia and Lundbeck A/S. He has received commercial support for research from Lundbeck A/S and Roche, and has ownership interests in Acousort AB, Axial Therapeutics and Enterin Inc. W.H.O. has received personal honoraria for educational talks and/or consultancy, outside of the submitted work, from AbbVie, Adamas, Bristol-Myers Squibb, Desitin, Mundipharma, Neuropore, Novartis, Roche, and UCB Pharma and grants from the Deutsche For-schungsgemeinschaft, the International Parkinson-Fonds, The Netherlands, the Michael J. Fox Foundation, USA, the National Research Fond, Luxembourg, the Parkinson-Fonds Deutschland, and from Novartis Pharma, Germany. The other authors report no conflicts of interest."

"D.J.S. was supported by the JPB Foundation, NIH grants NS121174, and MJFF. P.B was supported by NIH grants 4R33NS106078 and 5R01DC016519. P.B. and M.X.H. are thankful for the support of Van Andel Institute. F.F.G. is thankful for the support of the ParkinsonFonds Deutschland. W.H.O. is a Hertie-Senior-Research Professor supported by the charitable Hertie-Foundation, Frankfurt/Main, Germany."